Search Result

Results for "

oral carcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (4) Antibiotic (1) Apoptosis (16) Autophagy (11) Bcl-2 Family (1) c-Met/HGFR (4) Caspase (2) CDK (8) COX (3) Deubiquitinase (1) DNA Alkylator/Crosslinker (3) DYRK (1) EGFR (4) ERK (2) Estrogen Receptor/ERR (2) FGFR (2) FXR (1) HCV (1) HDAC (1) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (3) Histone Acetyltransferase (2) Histone Methyltransferase (1) HSP (1) IAP (1) Influenza Virus (1) Isotope-Labeled Compounds (2) JAK (3) LXR (1) MDM-2/p53 (1) Na+/H+ Exchanger (NHE) (2) Necroptosis (1) NF-κB (2) p38 MAPK (4) PERK (1) PI3K (2) PKA (2) Prostaglandin Receptor (2) RAR/RXR (4) Reactive Oxygen Species (3) ROR (1) Sirtuin (1) SphK (1) Syk (2) TNF Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (2) Tyrosinase (1) VEGFR (2)
By Research Areas:	Cancer (62) Cardiovascular Disease (5) Endocrinology (1) Infection (1) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (1)

By Targets:

5-HT Receptor (1)

Akt (4)

Antibiotic (1)

Apoptosis (16)

Autophagy (11)

Bcl-2 Family (1)

c-Met/HGFR (4)

Caspase (2)

CDK (8)

COX (3)

Deubiquitinase (1)

DNA Alkylator/Crosslinker (3)

DYRK (1)

EGFR (4)

ERK (2)

Estrogen Receptor/ERR (2)

FGFR (2)

FXR (1)

HCV (1)

HDAC (1)

Hedgehog (1)

HIF/HIF Prolyl-Hydroxylase (3)

Histone Acetyltransferase (2)

Histone Methyltransferase (1)

HSP (1)

IAP (1)

Influenza Virus (1)

Isotope-Labeled Compounds (2)

JAK (3)

LXR (1)

MDM-2/p53 (1)

Na+/H+ Exchanger (NHE) (2)

Necroptosis (1)

NF-κB (2)

p38 MAPK (4)

PERK (1)

PI3K (2)

PKA (2)

Prostaglandin Receptor (2)

RAR/RXR (4)

Reactive Oxygen Species (3)

ROR (1)

Sirtuin (1)

SphK (1)

Syk (2)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

TRP Channel (2)

Tyrosinase (1)

VEGFR (2)

By Research Areas:

Cancer (62)

Cardiovascular Disease (5)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (7)

Metabolic Disease (2)

Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111458

GSK2643943A 3 Publications Verification	Deubiquitinase	Cancer
GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC₅₀ of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) .

HY-106735

Arotinoid Ro 13-6298; Arotinoid ethyl ester	RAR/RXR	Inflammation/Immunology Cancer
Arotinoid (RO 13-6298) is a retinoid, and acts as an orally active and highly potent agonist of retinoic acid receptors (RARs) with antipsoriatic effects. Arotinoid has antipapiltoma activity with an ED₅₀ of 0.05 mg/kg. Arotinoid can be used for the research of skin carcinomas .

HY-155785

MTP	Apoptosis Autophagy Reactive Oxygen Species JAK	Cancer
MTP is a PKM2 inhibitor. MTP induces cancer cell apoptosis by modulating caspase-3 activation. MTP induces autophagy and increases ROS generation. MTP also inhibits JAK2 signaling. MTP can be used for research of oral squamous cell carcinoma .

HY-144254

PI3Kδ-IN-10	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-10 is a highly potent and orally active PI3Kδ inhibitor with IC₅₀ of 2 nM. PI3Kδ-IN-10 robustly suppresses the downstream AKT pathway to induce subsequent apoptosis in hepatocellular carcinoma models .

HY-106364

Peplomycin Bleomycin PEP; Pepleomycin	Antibiotic	Cancer
Peplomycin (Bleomycin PEP; Pepleomycin) is an antibiotic analogue of Bleomycin (HY-108345), with high antitumor effect and less pulmonary toxicity. Peplomycin induce apoptosis in oral squamous carcinoma cell line SSCKN cells and pulmonary fibrosis in rats .

HY-151461

CHNQD-01255

Others Cancer

CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .

CHNQD-01255	Others	Cancer
CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .

HY-N1261

Scutebarbatine B	Others	Cancer
Scutebarbatine B shows significant cytotoxic activities against three human cancer lines, namely, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells, with IC₅₀ values in the range 3.5-8.1 mM ^[1]<

HY-101840A

EIPA hydrochloride 35+ Cited Publications L593754 hydrochloride; MH 12-43 hydrochloride; Ethylisopropylamiloride hydrochloride	TRP Channel Autophagy COX Prostaglandin Receptor Na+/H+ Exchanger (NHE)	Inflammation/Immunology Cancer
EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na ⁺/H ⁺-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .

HY-101840

EIPA 35+ Cited Publications L593754; MH 12-43; Ethylisopropylamiloride	TRP Channel Prostaglandin Receptor Autophagy COX Na+/H+ Exchanger (NHE)	Inflammation/Immunology Cancer
EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA also enhances autophagy by inhibiting Na ⁺/H ⁺-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .

HY-14653

Amsilarotene TAC-101; Am 555S	RAR/RXR Apoptosis	Cancer
Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with K_i of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer .

HY-N8380

(-)-Latifolin	Apoptosis Autophagy PI3K Necroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-108527

CD1530	RAR/RXR	Cancer
CD1530 is a selective RARγ agonist with an K_d of 150 nM . CD1530 has been used in combination with bexarotene to inhibit oral carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide in a mouse model of human oral-cavity and esophageal squamous-cell carcinoma .

HY-119272

EF24	ERK Caspase	Cancer
EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .

HY-N0746

Oxysophocarpine 4 Publications Verification	Others	Cancer
Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides. Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the growth and metastasis of oral squamous cell carcinoma (OSCC) .

HY-153967

BLU0588 1 Publications Verification	PKA	Cancer
BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC₅₀ of 1 nM and dissociation constant (K_d) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research .

HY-13593

Chlorambucil 4 Publications Verification CB-1348; WR-139013	DNA Alkylator/Crosslinker	Cancer
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .

HY-103706

ROC-325	Autophagy Apoptosis	Cancer
ROC-325 is a potent and orally active autophagy inhibitor with a strong anticancer activity. ROC-325 induces the deacidification of lysosomes, accumulation of autophagosomes, and disrupted autophagic flux. ROC-325 also induces renal cell carcinoma apoptosis .

HY-N0530

Dryocrassin ABBA Dryocrassin	Apoptosis Influenza Virus	Cancer
Dryocrassin ABBA (Dryocrassin) is an orally active phloroglucinol derivative that can be extracted from Phyllopteris officinalis. Dryocrassin ABBA has antitumor and antiviral activity. Dryocrassin ABBA induced apoptosis of human hepatocellular carcinoma cells through mitochondrial pathway mediated by Caspase .

HY-100492

Fisogatinib 1 Publications Verification BLU-554	FGFR	Cancer
Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .

HY-114338

Dalpiciclib SHR-6390	CDK	Cancer
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-114338A

Dalpiciclib hydrochloride SHR-6390 hydrochloride	CDK	Cancer
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-101246

RPI-1
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .

HY-N3665

Cyclocommunol	Tyrosinase	Cancer
Cyclocommunol is a prenylflavonoid with antityrosinase and antiplatelet activitie, can be solated from breadfruit. Cyclocommunol exerts anti-tumor activity and inhibits the growth of human hepatoma and gastric cancer cells with IC₅₀ values between 16 and 80 µM. Cyclocommunol shows proapoptotic effect on oral squamous cell carcinoma (OSCC) .

HY-125840

Belzutifan 3 Publications Verification PT2977; MK-6482	HIF/HIF Prolyl-Hydroxylase	Cancer
Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC₅₀ of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .

HY-W010593

Ethylenethiourea	Others	Cancer
Ethylenethiourea is a degradation product of the ethylenebisthiocarbamate group of fungicides. Ethylenethiourea is tumorigenic and teratogenic. Ethylenethiourea is orally active .

HY-13593S

Chlorambucil-d8 CB-1348-d₈; WR-139013-d₈	Isotope-Labeled Compounds DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈ is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-13593S1

Chlorambucil-d8-1 CB-1348-d₈-1; WR-139013-d₈-1	Isotope-Labeled Compounds DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈-1 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-145835

PERK-IN-5	PERK	Cancer
PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC₅₀s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model .

HY-144614

JH-XVII-10	DYRK Apoptosis	Neurological Disease Cancer
JH-XVII-10 is a potent, selective and orally active DYRK1A and DYRK1B inhibitor with IC₅₀s of 3 nM and 5 nM for DYRK1A and DYRK1B, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines .

HY-119198

NSC745885	Apoptosis Histone Methyltransferase	Cancer
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .

HY-111226

GSK5182 2 Publications Verification	Estrogen Receptor/ERR Reactive Oxygen Species	Cardiovascular Disease Cancer
GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC₅₀ of 79 nM. GSK5182 does not interact with other nuclear receptors, including ERRα or ERα. GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma (HCC) .

HY-150072

DS89002333	PKA	Cancer
DS89002333 is an orally active and potent PRKACA inhibitor, with an IC₅₀ of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .

HY-16706

Remodelin 5+ Cited Publications	Histone Acetyltransferase	Cancer
Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model .

HY-W008634

Bropirimine	Toll-like Receptor (TLR)	Cancer
Bropirimine is a synthetic agonist for toll-like receptor 7 (TLR7). Bropirimine inhibits differentiation of osteoclast precursor cells into osteoclasts via TLR7-mediated production of IFN-β. Bropirimine is an orally active immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary tract .

HY-50767

Palbociclib Maximum Cited Publications 134 Publications Verification PD 0332991	CDK	Cancer
Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-111226A

(E/Z)-GSK5182	Estrogen Receptor/ERR Reactive Oxygen Species	Cardiovascular Disease Cancer
(E/Z)-GSK5182 is a racemic compound of (E)-GSK5182 and (Z)-GSK5182 isomers. GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC₅₀ of 79 nM . GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma .

HY-50767B

Palbociclib dihydrochloride PD-0332991 dihydrochloride	CDK	Cancer
Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767C

Palbociclib hydrochloride 115+ Cited Publications PD-0332991 hydrochloride	CDK	Cancer
Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767A

Palbociclib monohydrochloride Maximum Cited Publications 134 Publications Verification PD 0332991 monohydrochloride	CDK	Cancer
Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-A0065

Palbociclib isethionate Maximum Cited Publications 134 Publications Verification PD 0332991 isethionate	CDK	Cancer
Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-16706A

Remodelin hydrobromide 5+ Cited Publications	Histone Acetyltransferase	Cancer
Remodelin hydrobromide is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin hydrobromide inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin hydrobromide inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin hydrobromide enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model .

HY-50767D

Palbociclib orotate PD 0332991 orotate	CDK	Cancer
Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-103018

Gusacitinib 1 Publications Verification ASN-002	JAK Syk	Inflammation/Immunology Cancer
Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-103018A

Gusacitinib hydrochloride ASN-002 hydrochloride	JAK Syk	Inflammation/Immunology Cancer
Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Cancer
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-17473

Embelin 4 Publications Verification Embelic acid; Emberine; NSC 91874	IAP NF-κB Apoptosis Autophagy	Cancer
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC₅₀=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .

HY-110088

SCH529074 1 Publications Verification	MDM-2/p53	Cancer
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a K_i of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .

HY-147203

5-HT2B antagonist-1	5-HT Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC₅₀ value of 33.4 nM. 5-HT2B antagonist-1 can be used in studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease or gastrointestinal disease .

HY-100491

H3B-6527	FGFR	Cancer
H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC₅₀ of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC₅₀s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .

HY-122214

AC-73 3 Publications Verification	Autophagy	Cancer
AC-73 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disrupts CD147 dimerization, thereby mainly suppressing the CD147/ERK1/2/STAT3/MMP-2 pathways. AC-73 inhibits the motility and invasion of hepatocellular carcinoma cells . AC-73 is also an anti-proliferative agent and an inducer of autophagy in leukemic cells .

Cat. No.	Product Name	Category	Target	Chemical Structure